Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
-
REGULATORY MHLW Study Group to Ponder Support Measures for Stable Generic Supplies
September 6, 2022
-
ORGANIZATION Chuikyo Payer Rep Eyes 5%-Plus Discrepancy Threshold or Broader Coverage: 2023 Off-Year Re-Pricing
September 5, 2022
-
ACADEMIA Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
September 5, 2022
-
ORGANIZATION FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
September 2, 2022
-
REGULATORY Japan to Supply AstraZeneca’s Evusheld Only for COVID-19 Prevention
September 2, 2022
-
REGULATORY New Expert Panel on Drug Distribution and Pricing Boots Up; 2-Step Proposals Eyed for Off-Year Revision, 2024 Reform
September 1, 2022
-
ORGANIZATION JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
August 31, 2022
-
REGULATORY University of Tokyo Selected as Flagship R&D Site to Orchestrate Japan’s Vaccine Efforts: SCARDA Project
August 31, 2022
-
REGULATORY Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
August 30, 2022
-
REGULATORY AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
-
COMMENTARY Tussle in Japan Diabetes Market Heating Up; BI and Sumitomo Nip and Tuck for No. 1 Slot
August 29, 2022
-
REGULATORY Lilly’s Tirzepatide in Line for Approval as Early as September as Japan’s 1st GIP/GLP-1 Agent
August 26, 2022
-
REGULATORY Japan Approves Label Expansions for Lynparza, Ultomiris, Keytruda, Tagrisso, and More
August 25, 2022
-
BUSINESS BMS Wants to Jolt Cancer Care Landscape with Broader I/O Combo Options, Pursuing LAG-3 Inhibitor in Japan Too
August 24, 2022
-
REGULATORY MHLW to Boost Orphan Program to Fuel New Drug Development: FY2023 Budget Request
August 23, 2022
-
REGULATORY After Repeated Scandals, PMDA Sets Up New Division to Provide GMP Inspection Know-How to Prefectures
August 22, 2022
-
REGULATORY Operational Issues of Emergency Approval Scheme Will Be Addressed If Needed: Pharma Bureau Chief
August 19, 2022
-
BUSINESS Lagevrio Joins NHI Price List, Normal Distribution to Start Once Ready
August 19, 2022
-
BUSINESS Incyte Japan Urges Reward for Innovation in Rare Diseases as Pemazyre Filed for Ultra Orphan Cancer
August 18, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…